Search

Displaying results 5771 - 5780 of 10000 in total
  1. Drug

    NTx-265

    go.drugbank.com/drugs/DB05649
    Investigational

    In May 2006, biotechnology company Stem Cell Therapeutics started a Phase IIa study of NTx-265. … NTx-265 is a combination of two currently marketed large molecules designed to stimulate the growth and differentiation of neural stem cells in adults who have suffered a stroke – the second leading cause

  2. Drug

    BZL101

    go.drugbank.com/drugs/DB05051
    Investigational

    BZL101 is an oral drug designed for the treatment of advanced breast cancer with a novel mechanism of action. BZL101 targets diseased cells while leaving normal cells healthy and intact.

  3. Drug

    Ferrous glycine sulfate

    go.drugbank.com/drugs/DB14501
    Approved

  4. Drug

    Nitarsone

    go.drugbank.com/drugs/DB11437
    ExperimentalVet approved

    Nitarsone is an organoarsenic compound. It is used as an additive in poultry feed to improve weight gain and feed efficiency, while preventing blackhead disease.

  5. Drug

    Pamiparib

    go.drugbank.com/drugs/DB14769
    Investigational

    on Substrate Poly ADP Ribose Polymerase Inhibitbor (PARPI) or Chemotherapy). … Pamiparib is under investigation in clinical trial NCT03933761 (Pamiparib in Fusion Positive, Reversion Negative High Grade Serous Ovarian Cancer or Carcinosarcoma With BRCA1/2 Gene Mutations If Progression

  6. Drug

    Lutetium (177Lu) NeoB

    go.drugbank.com/drugs/DB30389
    Investigational

    Lutetium (177Lu) NeoB is under investigation in clinical trial NCT06379217 (NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine

  7. Drug

    AZX-100

    go.drugbank.com/drugs/DB06323
    Investigational

  8. Drug

    AMGN-0007

    go.drugbank.com/drugs/DB06511
    Experimental

    Recombinant osteoprotegerin (AMGN-0007) is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease.

  9. Drug

    LX201

    go.drugbank.com/drugs/DB04943
    Investigational

    LX201 is implanted subconjunctivally (beneath the transparent membrane covering the white of the eye) in a minimally invasive procedure. … The implant is being developed clinically for the prevention of rejection in corneal transplantation. It is being developed by Lux Biosciences, Inc.

  10. Drug

    Denibulin

    go.drugbank.com/drugs/DB05932
    Experimental

    Denibulin is a novel small molecule Vascular Disrupting Agent under development by MediciNova for treatment of solid tumor cancers.